Traders should expect a sharp decline in CPRX shares upon delisting. The stock will likely move to the OTC markets with significantly reduced liquidity. Any remaining positions should be evaluated for exit before the delisting takes full effect. Monitor for any subsequent going-private transaction or bankruptcy filing.
CPRX drugs
CPRX drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK AT ENTRY AT T+5- T+0 · Jul 15 $31.49entry
- T+1 · 4mo ago 0.00%α +0.54% · $31.49
- T+5 · 4mo ago 0.00%α +0.98% · $31.49
- T+20 · due 3mo ago Pending
- T+60 · due 6w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nasdaq filed a Form 25-NSE to delist Catalyst Pharmaceuticals' common stock under Rule 12d2-2(a)(3), effective immediately on July 15, 2026. This is a mandatory removal initiated by the exchange, not a voluntary delisting, and represents a severe negative event for a $3.9B market-cap company.
Key Facts
- Nasdaq Stock Market LLC filed Form 25-NSE to remove Catalyst Pharmaceuticals' common stock from listing and registration.
- The delisting is under 17 CFR 240.12d2-2(a)(3), which covers securities that have been redeemed, retired, or matured, but here it is an exchange-initiated removal.
- The filing was made effective on July 15, 2026.
- Catalyst Pharmaceuticals has a market cap of approximately $3.9B, making this a significant event.
Financial Impact
Delisting from Nasdaq, loss of exchange listing, likely severe price decline, reduced liquidity, and potential forced selling by institutional holders.
Risk Factors
- Complete loss of exchange listing and trading halts.
- Forced selling by institutional investors who cannot hold OTC stocks.
- Potential default on debt covenants tied to exchange listing.
- Risk of further regulatory or legal actions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 25-NSE Filing (CPRX), Batch item 1 | 0001354457-26-000694 |
| Document: 0001354457-26-000694-index-headers.html | 0001354457-26-000694 |
| Document: 0001354457-26-000694-index.html | 0001354457-26-000694 |
| Document: 0001354457-26-000694.txt | 0001354457-26-000694 |
| 25-NSE Filing (CPRX), Batch item 5 | 0001354457-26-000694 |
| Document: 0001354457-26-000694-index-headers.html | 0001354457-26-000694 |
| Document: 0001354457-26-000694-index.html | 0001354457-26-000694 |
| Document: 0001354457-26-000694.txt | 0001354457-26-000694 |
Track record
16 reports on CPRX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
- Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
- Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
- Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
- Jul 15, 202617w ago 25-NSE Bearish 9/10 Viewing Entry $31.49 No price data
- Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
- Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
- Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
- May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
- May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers